2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist

J Pharmacol Exp Ther. 2004 Jun;309(3):1124-31. doi: 10.1124/jpet.103.064584. Epub 2004 Feb 19.

Abstract

A peptide corresponding to a proteinase-activated receptor 2 (PAR(2))-activating peptide with an N-terminal furoyl group modification, 2-furoyl-LIGRLO-NH(2), was assessed for PAR(2)-dependent and -independent biological activities. 2-Furoyl-LIGRLO-NH(2) was equally effective to and 10 to 25 times more potent than SLIGRLNH(2) for increasing intracellular calcium in cultured human and rat PAR(2)-expressing cells, respectively. In bioassays of tissue PAR(2) activity, measured as arterial vasodilation and hyperpolarization, 2-furoyl-LIGRLO-NH(2) was 10 to 300 times more potent than SLIGRL-NH(2). Unlike trans-cinnamoyl-LIGRLO-NH(2), 2-furoyl-LI-GRLO-NH(2) did not cause a prominent non-PAR(2)-mediated contraction of murine femoral arteries. In conclusion, 2-furoyl-LI-GRLO-NH(2) represents the most potent and selective activator of PAR(2) in biological systems described to date.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amides / pharmacology
  • Animals
  • Aorta / drug effects
  • Aorta / physiology
  • Electrophysiology
  • Femoral Artery
  • Humans
  • Male
  • Mesenteric Arteries / drug effects
  • Mesenteric Arteries / physiology
  • Mice
  • Mice, Inbred C57BL
  • Oligopeptides / pharmacology*
  • Peptides / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, PAR-2 / agonists*
  • Receptor, PAR-2 / metabolism
  • Vascular Resistance / drug effects

Substances

  • 2-furoyl-LIGRLO-amide
  • Amides
  • Oligopeptides
  • Peptides
  • Receptor, PAR-2
  • seryl-leucyl-isoleucyl-glycyl-arginyl-leucine